Merck Scraps Two Late-Stage Keytruda Studies on Disappointing Data

Merck (MRK) decided to discontinue two separate phase III studies, KEYNOTE-867 and KEYNOTE-630, evaluating its blockbuster drug Keytruda in patients with certain types of lung cancer and skin cancer, respectively.Merck took the decision based on the recommendations of an independent data monitoring committee (IDMC), which reviewed the interim data on both studies and concluded that the therapy’s risk/benefit profile did not support continuing either of the studies.Merck’s Lung Cancer Study Fails to Meet Goa ...